Zolpidem Sublingual Tablets, 1.75 mg and 3.5 mg are AB-rated generic equivalent of Purdue Pharma L.P’s Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Pharma major Lupin announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the first product from its GAVIS pipeline, Zolpidem Sublingual Tablets, 1.75 mg & 3.5 mg to market a generic equivalent of Purdue Pharma L.P’s Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg, having received final approval from the United States Food & Drug Administration (FDA) earlier, as well as final clearance from the FTC with 180 days of exclusivity.
Zolpidem Sublingual Tablets, 1.75 mg and 3.5 mg are AB-rated generic equivalent of Purdue Pharma L.P’s Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Intermezzo had US sales of USD 9.46 million (IMS MAT December 2015).
Lupin Ltd is currently trading at Rs. 1466, up by Rs. 4.7 or 0.32% from its previous closing of Rs. 1461.3 on the BSE.
The scrip opened at Rs. 1465 and has touched a high and low of Rs. 1478.25 and Rs. 1447 respectively. So far 1736787(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 65843.69 crore.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs. 1502.55 and Rs. 1294.05 respectively.
The promoters holding in the company stood at 46.53 % while Institutions and Non-Institutions held 43.56 % and 9.92 % respectively.
The stock is currently trading below its 200 DMA.
Zolpidem Sublingual Tablets, 1.75 mg and 3.5 mg are AB-rated generic equivalent of Purdue Pharma L.P’s Intermezzo Sublingual Tablets, 1.75 mg & 3.5 mg and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Intermezzo had US sales of USD 9.46 million (IMS MAT December 2015).
Lupin Ltd is currently trading at Rs. 1466, up by Rs. 4.7 or 0.32% from its previous closing of Rs. 1461.3 on the BSE.
The scrip opened at Rs. 1465 and has touched a high and low of Rs. 1478.25 and Rs. 1447 respectively. So far 1736787(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 65843.69 crore.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs. 1502.55 and Rs. 1294.05 respectively.
The promoters holding in the company stood at 46.53 % while Institutions and Non-Institutions held 43.56 % and 9.92 % respectively.
The stock is currently trading below its 200 DMA.
No comments:
Post a Comment